JPRN-UMIN000004807
Completed
未知
Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutation - Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutation
KantoKoshinetsu lung cancer research group0 sites20 target enrollmentDecember 29, 2010
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- KantoKoshinetsu lung cancer research group
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) patients who has interstitial pneumonia identified by chest CT or by blood test (2\) (3\) Patients with EGFR mutation (T790M) which is NOT expected the good response with gefitinib. (4\) Patients with uncontrollable complications (5\) Pregnant or lactation women, or women with known or suspected pregnancy (6\) Patients with severe malabsorption syndrome or with severe functional gastrointestinal disorder (7\) patients with systemic administration steroids over 4 weeks (8\) Patients with contraindication of gefitinib (9\) Patients with active concomitant malignancy (10\) Inappropriate patients for this study judged by the physicians
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase II Study of Gefitinib Monotherapy as First-Line Treatment for Elderly Patients with Stage IIIB /IV Adenocarcinoma of the LungJPRN-UMIN000006144Central Japan Lung Study Group32
Completed
Not Applicable
Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.non-small cell lung cancerJPRN-UMIN000000637Juntendo University, School of Medicine20
Recruiting
Not Applicable
Efficacy and safety of gefitinib monotherapy for all types of refractory cancer patients with EGFR amplificatioKCT0004066Samsung Medical Center3
Completed
Phase 2
A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000001863Central Japan Lung Study Group19
Completed
Not Applicable
Analysis of Gefitinib(Drug) in lung cancer.Health Condition 1: null- Lung Cancer PatientsCTRI/2017/05/008490Tata Memorial Hospital350